Joseph Haas

Executive Summary Having earlier shown efficacy as adjunctive therapy, AbbVie is waiting for data from a third Phase III trial before determining filing plans for the D1/D5 receptor agonist.

Executive Summary One of Enanta's two antivirals in development for RSV showed efficacy in a healthy patient challenge trial.

Executive Summary A new contender emerges in obesity with pipeline assets from Jiangsu Hengrui, including a Phase III dual agonist, and an experienced team already focused on commercial hurdles.

Executive Summary Plus deals involving Jiangsu Alphamab/CSPC, Zydus/CDRI, Junshi/JSIAMA, Repair/Genevant, Sanofi/I-Mab, Novartis/Mitem and BioAtla/Context.

Executive Summary Avidity hopes to complete enrollment in mid-2025 for an ongoing Phase III trial of its antibody-oligonucleotide conjugate in myotonic dystrophy type 1, which has no approved drug therapy.

Executive Summary Big pharmas, biotechs and the US government look to partner with artificial intelligence and machine learning firms for discovery efforts across therapeutic areas and modalities.

Executive Summary All big pharmas have proprietary artificial intelligence or machine learning platform or are partnering with third parties, according to a survey by S&P Global.

Executive Summary PD-1 inhibitor Opdivo has obtained US FDA approval for pre- and post-surgical treatment in operable non-small cell lung cancer, but Merck and AstraZeneca got there first.

Executive Summary Phase III success positions Scholar Rock's selective myostatin inhibitor for regulatory filings in early 2025.

Executive Summary Dalzanemdor missed its primary endpoint in a Phase II Parkinson's study, Sage announced, following April's Phase II miss in Alzheimer's.